The safety concerns regarding immune checkpoint inhibitors in liver cancer patients rising mainly from CHB

Aim: To analyze the safety of immune checkpoint inhibitors in primary liver cancer patients and to identify the risk factors for immune-related adverse events (irAEs). Methods: The study enrolled 106 patients with primary liver cancer, including 81 with hepatocellular carcinoma and 25 with intrahepa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lou, Shike, Cao, Zhujun, Chi, Wanqing, Wang, Xiaoyin, Feng, Mingyang, Lin, Lanyi, Ding, Yezhou, Liu, Kehui, Qu, Lihong, Zhao, Gangde, Bao, Shisan, Wang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165088/
https://www.ncbi.nlm.nih.gov/pubmed/37168999
http://dx.doi.org/10.3389/fphar.2023.1164309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165088/
https://www.ncbi.nlm.nih.gov/pubmed/37168999
http://dx.doi.org/10.3389/fphar.2023.1164309

Ejemplares similares